skip to main content

United Therapeutics Corporation to Present at Goldman Sachs 40th Annual Global Healthcare Conference

SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., June 5, 2019 /PRNewswire/ -- United Therapeutics Corporation (Nasdaq: UTHR) announced today that James Edgemond, Chief Financial Officer and Treasurer of United Therapeutics, will provide an overview and update on the company's business at the Goldman Sachs 40th Annual Global Healthcare Conference in Rancho Palos Verdes, CA.

The presentation will take place on Tuesday, June 11, 2019, at 1:20 PM Pacific Time, and can be accessed via a live webcast on the United Therapeutics website at http://www.unither.com under the "Investors" tab in the "Events and Presentations" section. An archived, recorded version of the presentation will be available approximately twenty-four hours after the presentation ends and can be accessed at the same location for 90 days. [uthr-g]

Cision View original content:http://www.prnewswire.com/news-releases/united-therapeutics-corporation-to-present-at-goldman-sachs-40th-annual-global-healthcare-conference-300861164.html

SOURCE United Therapeutics Corporation

Recent Press Releases

Nebulized Tyvaso® (treprostinil) Inhalation Solution demonstrated superiority over placebo for the change in absolute forced vital capacity by 130.1 mL and reduced the risk of clinical worsening in patients with...
The pivotal study of Tyvaso® (treprostinil) Inhalation Solution demonstrated a statistically significant preservation of lung function across all subgroups, as measured by absolute forced vital capacity (FVC), and fewer...
Agreements for aggregate $1.5 billion Accelerated Share Repurchase (ASR) already executed, with an additional $500 million authorized within the next yearSILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS...
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)-- United Therapeutics Corporation (Nasdaq: UTHR) announced today that Dr.Martine Rothblatt,Chairperson and Chief Executive Officer, will provide a...
The phase 3 ADVANCE OUTCOMES study of ralinepag met its primary endpoint and several important secondary endpoints, including increasing odds of clinical improvement by 47%, in predominantly pre-treated patients with...
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)-- United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced its financial results for the quarter and year ended...